Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Rett Syndrome Therapeutics Report - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 19 Dec 17

The "Rett Syndrome - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Rett Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 7, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Rett Syndrome - Overview
  2. Rett Syndrome - Therapeutics Development
  3. Pipeline Overview
  4. Pipeline by Companies
  5. Pipeline by Universities/Institutes
  6. Products under Development by Companies
  7. Products under Development by Universities/Institutes
  8. Rett Syndrome - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Rett Syndrome - Companies Involved in Therapeutics Development
  • AMO Pharma Ltd
  • Amorsa Therapeutics Inc
  • Anavex Life Sciences Corp
  • Apteeus
  • ArmaGen Inc
  • AveXis Inc
  • BioElectron Technology Corp
  • Biohaven Pharmaceutical Holding Company Ltd
  • Eloxx Pharmaceuticals Ltd
  • GW Pharmaceuticals Plc
  • Mitochon Pharmaceuticals Inc
  • Mitsubishi Tanabe Pharma Corp
  • Neuren Pharmaceuticals Ltd
  • Neurolixis Inc
  • Newron Pharmaceuticals SpA
  • OPKO Health Inc
  • Sage Therapeutics Inc
  • Ultragenyx Pharmaceutical Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 19/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.